This post-hoc analysis characterized the weekly incidence and overall duration of common early-onset treatment-emergent adverse events (TEAEs) during solriamfetol treatment.
Participants (obstructive sleep apnea [OSA], N=474; narcolepsy, N=236) were randomized to 12 weeks of placebo or solriamfetol 37.5 (OSA only), 75, 150, or 300 mg. For common early-onset TEAEs (those occurring in ≥5% of participants in any solriamfetol dose group and with a higher incidence than that observed in placebo-treated participants during week 1), the incidence of new occurrence or change in severity over time was calculated for each subsequent study week. Data were analyzed separately for each study and summarized by placebo and combined solriamfetol groups.
Common early-onset TEAEs (at doses ≤150 mg, ie, approved doses) included headache (OSA, 5.1%; narcolepsy, 8.5%), nausea (OSA, 2.5%; narcolepsy, 4.2%), decreased appetite (OSA, 4.2%; narcolepsy, 5.9%), as well as anxiety (2.1%), insomnia (1.3%), and feeling jittery (3.0%) in OSA and dry mouth (4.2%) in narcolepsy. Incidence of common early-onset TEAEs was highest at week 1 and decreased over time. In OSA at doses ≤150 mg, headache, nausea, and feeling jittery had median durations ≤8 days, whereas decreased appetite, anxiety, and insomnia had longer durations. In narcolepsy at doses ≤150 mg, headache and nausea had median durations ≤8 days, whereas decreased appetite and dry mouth had longer durations. Most TEAEs were mild to moderate in severity.
Common early-onset TEAEs with solriamfetol are limited in duration, with the majority subsiding during the first week of treatment.
NCT02348593; NCT02348606.

© 2021 American Academy of Sleep Medicine.

Author